Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Anne Montfort; Thomas Filleron; Mathieu Virazels; Carine Dufau; Jean Milhès; Cécile Pagès; Pascale Olivier; Maha Ayyoub; Muriel Mounier; Amélie Lusque; Stéphanie Brayer; Jean-Pierre Delord; Nathalie Andrieu-Abadie; Thierry Levade; Céline Colacios; Bruno Ségui; Nicolas Meyer

doi:10.1158/1078-0432.CCR-20-3449

Clinical Trials: Immunotherapy

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Anne Montfort, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pagès, Pascale Olivier, Maha Ayyoub, Muriel Mounier, Amélie Lusque, Stéphanie Brayer, Jean-Pierre Delord, Nathalie Andrieu-Abadie, Thierry Levade, Céline Colacios, Bruno Ségui and Nicolas Meyer

Anne Montfort

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Thomas Filleron

3Methodology, biostatistics and clinical operations, Institut Claudius Regaud, IUCT-O, Toulouse, France.

4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Thomas Filleron

Mathieu Virazels

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Mathieu Virazels

Carine Dufau

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

5Université Toulouse III - Paul Sabatier, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jean Milhès

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Cécile Pagès

4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.

6Service d'Oncodermatologie, IUCT-O, CHU de Toulouse, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Pascale Olivier

7Service de Pharmacologie médicale et clinique, Centre Régional de Pharmacovigilance, de Pharmacoépidémiologie et d'information sur le médicament du CHU de Toulouse, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Maha Ayyoub

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.

5Université Toulouse III - Paul Sabatier, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Muriel Mounier

3Methodology, biostatistics and clinical operations, Institut Claudius Regaud, IUCT-O, Toulouse, France.

4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amélie Lusque

3Methodology, biostatistics and clinical operations, Institut Claudius Regaud, IUCT-O, Toulouse, France.

4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stéphanie Brayer

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

6Service d'Oncodermatologie, IUCT-O, CHU de Toulouse, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jean-Pierre Delord

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.

5Université Toulouse III - Paul Sabatier, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Jean-Pierre Delord

Nathalie Andrieu-Abadie

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Nathalie Andrieu-Abadie

Thierry Levade

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

5Université Toulouse III - Paul Sabatier, Toulouse, France.

8Laboratoire de Biochimie, Institut Fédératif de Biologie, CHU Purpan, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Céline Colacios

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

5Université Toulouse III - Paul Sabatier, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bruno Ségui

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

5Université Toulouse III - Paul Sabatier, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: bruno.segui@inserm.fr meyer.n@chu-toulouse.fr

Nicolas Meyer

1INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

2Equipe Labellisée Fondation ARC pour la recherche sur le cancer, Toulouse, France.

4Institut Universitaire du Cancer (IUCT-O), Toulouse, France.

5Université Toulouse III - Paul Sabatier, Toulouse, France.

6Service d'Oncodermatologie, IUCT-O, CHU de Toulouse, Toulouse, France.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: bruno.segui@inserm.fr meyer.n@chu-toulouse.fr

DOI: 10.1158/1078-0432.CCR-20-3449 Published February 2021

Article
Figures & Data
Info & Metrics
PDF

This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

PreviousNext

February 2021
Volume 27, Issue 4

Table of Contents
Table of Contents (PDF)
About the Cover
Editorial Board (PDF)

Search for this keyword

View this article with LENS

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Message Subject (Your Name) has forwarded a page to you from Clinical Cancer Research

Message Body (Your Name) thought you would be interested in this article in Clinical Cancer Research.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Clin Cancer Res February 15 2021 (27) (4) 1037-1047; DOI: 10.1158/1078-0432.CCR-20-3449

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Clin Cancer Res February 15 2021 (27) (4) 1037-1047; DOI: 10.1158/1078-0432.CCR-20-3449

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Main menu

User menu

Search

Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial

Purchase access

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Articles

Info for

About Clinical Cancer Research